Author(s):
Rodrigues, Célia Fortuna ; Gonçalves, Bruna ; Rodrigues, E. ; Silva, Sónia Carina ; Azeredo, Joana ; Henriques, Mariana
Date: 2015
Persistent ID: http://hdl.handle.net/1822/37877
Origin: RepositóriUM - Universidade do Minho
Project/scholarship:
info:eu-repo/grantAgreement/FCT/5876-PPCDTI/119069/PT
;
info:eu-repo/grantAgreement/FCT/5876-PPCDTI/126270/PT
;
info:eu-repo/grantAgreement/FCT/COMPETE/126270/PT;
info:eu-repo/grantAgreement/FCT/3599-PPCDT/132966/PT;
info:eu-repo/grantAgreement/FCT/COMPETE/119069/PT;
Subject(s): Candida glabrata; Biofilms; Resistance mechanisms; Antifungals; Matrix; Science & Technology; Ciências Médicas::Biotecnologia Médica
Description
Candida glabrata is the second most prevalent yeast in fungal infections, especially in immunocompromised and/or hospitalized patients. The azole resistance within this species is very well-known and results in a low therapeutic response of C. glabrata infections, particularly when associated with biofilms. Objective - To understand the different efficacies of two azoles against C. glabrata biofilms: - fluconazole (Flu), a long time used drug - voriconazole (Vcz), a latest drug used only in hospitals.
Programa Operacional, Fatores de competitividade – COMPETE and by national funds through FCT – Fundação para a Ciência e a TecnologiaonthescopeoftheprojectsFCT PTDC/SAU-MIC/119069/2010, RECI/EBB- EBI/0179/2012, PEst-OE/EQB/LA0023/2013 Project “BioHealth - Biotechnology and Bioengineering approachesto improvehealthquality",Ref. NORTE-07-0124-FEDER-000027, co-funded by the Programa Operacional Regional do Norte (ON.2 – O Novo Norte), QREN, FEDER